Headline:	Covid-19 treatments and their role in war against pandemic				
Media Title:	The Straits Times (Home) (Mon-Wed)		**Date:**	2020-11-16	
Section:	Science	**Page No:**	B12_B13	**Size:**	100x36

Science/Talk

Covid-19 treatments and their role in war against pandemic

Damien O'Connell and Daniell Lee
For The Straits Times

The world is currently focused on the development of Covid-19 vaccines, with the expectation that these will protect the healthy population and allow for a return to normality.

However, it is important to bear in mind that not everyone will respond equally well to a vaccine.

Indeed, it is likely that there will be a significant number of individuals who are either non-responders or who already have been infected.

This is where therapeutics come in, to treat infected patients and/or prevent infection.

Researchers and clinicians have been working hard to find the right mix of therapeutics to treat patients suffering from the disease.

Like vaccines for infectious diseases, one of the quickest routes to treatment is to repurpose existing drugs that have been used to treat similar diseases.

These drugs have already been approved by regulatory bodies for other indications and, therefore, their potential use to treat or protect against Covid-19 can be achieved faster than developing entirely new drugs.

Take the antiviral drug remdesivir, for example. First created to treat Ebola, it has been used as part of clinical trials for Covid-19 patients and has recently been fully granted conditional approval by the Health Sciences Authority to treat patients who are severely ill Covid-19 patients.

However, repurposed drugs have limitations in terms of specificity and efficacy.

Remdesivir, for example, initially touted as effective against Covid-19 were eventually found to have minimal benefits or even to have adverse effects.

One approach to get high-quality evidence about the safety and efficacy of the drugs in an accelerated timeframe is to conduct large-scale randomised controlled trials involving large numbers of patients.

The Solidarity trial, the Recovery trial, the World Health Organisation Solidarity trial, and the United States National Institutes of Health's (NIH) Adaptive Covid-19 Treatment Trial are all running Covid-19 Therapeutic Interventions and Vaccines (Activ) trial, which have recruited thousands of patients over two to four months.

Indeed, these trials have shown that some of the repurposed drugs are effective therapeutics, while lopinavir-ritonavir and hydroxychloroquine are not.

Clearly, other therapeutic approaches besides repurposed drugs are required.

HARNESSING ANTIBODIES TO HELP THE BODY FIGHT COVID-19

A more effective, but lengthier and costlier, way to develop drugs for Covid-19 therapeutics is to develop an entirely new antiviral drug. Such a drug would be specific to the Sars-CoV-2 virus that causes Covid-19 and would be designed using the body's immune response to infection.

There are two broad categories of antiviral treatments: small molecules and large molecules, referring to the molecular size of the treatment particles.

Small molecule drugs are commonly used today, and are typically chemically based and taken orally. Large molecule drugs are a relatively newer approach based on biologics and are typically administered via injections.

A potential treatment that offers much hope for Covid-19 patients at present is large molecule antibody-based therapy.

Antibodies are the body's soldiers, formed to fight off invaders like viruses and bacteria that are generated by our immune systems and have the potential to be used to treat, prevent or diagnose infection, and can be mass-produced in the laboratory relatively rapidly.

One way to manufacture antibody treatments is to harness the blood plasma of recovered Covid-19 patients, which is also called convalescent plasma.

Convalescent plasma can be used to treat Covid-19 patients, as we saw re-use high-quality published evidence to draw definitive conclusions on its relative efficacy and safety.

Moreover, the extraction and purification of convalescent plasma into therapeutic drug products is challenging, and large amounts of plasma are required to produce a uniform product in sufficient quantities, limiting the number of people who can be treated with this approach.



ST ILLUSTRATION: CEL ELAPA

Data from comparisons across previous Covid-19 treatments which have not been approved yet are given cognostically. If a person can convalescent plasma in the US also has been approved for use in high-risk levels that are potentially effective in improving survival in severe Covid-19 patients.

Antibodies can also be mass produced in the laboratory.

Known as monoclonal antibodies (mAbs), they are identical immune proteins made by a single clone of a white blood cell called the B cell. They can serve as substitute antibodies that can neutralise, enhance or mimic the immune system's attack on disease cells.

Recent advances in antibody engineering have allowed for the rapid screening of patient antibodies against Sars-CoV-2 from previous infections.

The main target of Sars-CoV-2 neutralising mAbs is the surface spike glycoprotein that gives the coronavirus its characteristic crown-like spiky appearance. This protein paves the way for the virus entry into host cells.

All mAbs currently in development for Covid-19 are designed to, and work to block the virus from attaching and entering human cells.

In addition to their use in antiviral therapy, antibodies are also being tried in a new treatment strategy which can help to correct the body's overactive immune response in Covid-19 patients.

The intention is to combine the use of what is called an immunomodulatory mAb with an antiviral mAb to help the immune system and target the virus respectively.

This will allow physicians more time to provide supportive treatment for severely ill Covid-19 patients, and significantly improve clinical outcomes.

Besides antiviral molecular antibody treatments, there are several efforts to develop experimental drugs that target the virus and could be more effective and targeted at Covid-19.

These drugs work by inhibiting various enzymes or other viral proteins.

Emory University in the US is collaborating with other US institutions to test commercially available antiviral compound, and has announced the launch of two phase two clinical trials to test the efficacy of EIDD-2801 as an antiviral treatment for Covid-19.

Several other groups, such as Calithera Biosciences, Jubilant Life Sciences and Ichor Therapeutics, are working on other targets like proteases (enzymes which aid virus processes), but they are still in the early stages and have not yet been tested on people, underscoring the difficulty in finding small molecule drugs to the clinic.

GLOBAL EFFORTS IN DEVELOPING COVID-19 THERAPEUTICS

The pace of mAb development during the current outbreak has been unprecedented.

Typically, the time from discovery of an antibody to initiation of clinical trials has been reduced by nearly half, and it is possible that further large-scale trials of new mAbs could begin by early 2021.

Several Sars-CoV-2 mAbs are poised to enter clinical trials in the coming months, and governments are joining global efforts to develop antibody therapies to treat Covid-19.

Eleven drugs work by inhibiting various enzymes or other viral proteins.

Emory University in the US is collaborating with other US institutions to test commercially available antiviral compound, and has announced the launch of two phase two clinical trials to test the efficacy of EIDD-2801 as an antiviral treatment for Covid-19.

Several other groups, such as Calithera Biosciences, Jubilant Life Sciences and Ichor Therapeutics, are working on other targets like proteases (enzymes which aid virus processes), but they are still in the early stages and have not yet been tested on people, underscoring the difficulty in finding small molecule drugs to the clinic.

GLOBAL EFFORTS IN DEVELOPING COVID-19 THERAPEUTICS

The pace of mAb development during the current outbreak has been unprecedented.

Typically, the time from discovery of an antibody to initiation of clinical trials has been reduced by nearly half, and it is possible that further large-scale trials of new mAbs could begin by early 2021.

Several Sars-CoV-2 mAbs are poised to enter clinical trials in the coming months, and governments are joining global efforts to develop antibody therapies to treat Covid-19.

These